Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

NCT00993720 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of GLP-1 on insulin doses, risk of low blood sugar, and stomach emptying rate in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–50 · all sexes

Timeline Started 2009-10 · est. completion 2010-10

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT00993720 ↗

Description as written by the study sponsor.

The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.

Treatments tested

Liraglutide Drug

after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
Liraglutide Drug

after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
continuous insulin therapy Other

after optimal treatment with insulin, patients continue on insulin for four weeks

Main thing measured	insulin-dose
Sponsor	Hvidovre University Hospital
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00993720 ↗